Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-γ ELISPOT assay

被引:21
|
作者
Winstone, Nicola [1 ]
Guimaraes-Walker, Ana [1 ]
Roberts, Joanna [1 ]
Brown, Denise [1 ]
Loach, Vanessa [1 ]
Goonetilleke, Nilu [1 ]
Hanke, Tomas [1 ]
McMichael, Andrew J. [1 ]
机构
[1] Univ Oxford, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England
基金
英国医学研究理事会;
关键词
Clinical trial; DNA-MVA vaccines; HIV-1; Memory T cells; INFECTED RHESUS MACAQUES; HIV-1; VACCINE; PRECLINICAL EVALUATION; CLINICAL-TRIALS; RESPONSES; TYPE-1; MVA; MEMORY; GAG; IMMUNOGENICITY;
D O I
10.1002/eji.200839167
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Induction of a long-term immunological memory, which can expand and defend the host upon pathogen encounter, is the "holy grail" of vaccinology. Here, using a sensitive cultured IFN-gamma ELISPOT assay, we show that 50% (15 out of 30) of healthy, HIV-1/2-uninfected volunteers who received pTHr.HIVA DNA prime-modified vaccinia virus Ankara. HIVA boost vaccine regimen 1 to 3 1/2 years ago had detectable HIV-1-specific T-cell responses. These T cells, predominantly of the CD4(+) subtype, could proliferate and produce multiple cytokines in response to in vitro peptide stimulation. Peptide mapping studies showed that the vaccine-induced CD4(+) T cells were mostly directed toward epitopes targeted in HIV-1-infected individuals. In addition, we used the same assay to re-evaluate 51 volunteers from past vaccine trial IAVI-006 and corrected the previously reported 10% of vaccine responders to 50%. Thus, we confirmed that cultured assays are a valuable tool for studying T-cell memory. These results are discussed in the context of the current state-of-affairs of the HIV-1 vaccine field.
引用
收藏
页码:975 / 985
页数:11
相关论文
empty
未找到相关数据